Bacil Pharma (Small Cap - Potential Multibagger) Share Target 2025, 2026 To 2035
|
Bacil Pharma Limited |
|||
|
Price: ₹40.48 (-1.99%) | ||
| 52 Week Low: ₹10.20 52 Week High: ₹62.56 |
|||
| Market Capital: 27.73 Crore (Smallcap) | |||
| -> | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Bacil Pharma Share Price Target For 2025
- 1.1.1: Bacil Pharma Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Bacil Pharma Share Price Target For 2026
- 1.2.1: Bacil Pharma Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Bacil Pharma Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Bacil Pharma Financial Performance
- 3.0.1: Is Bacil Pharma A Good Buy For Long Term?
Bacil Pharma, a Small Cap company has delivered 2144.6% returns in 5-year, making it a potential Multibagger.
To predict the Bacil Pharma's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Bacil Pharma Share Price Target For 2025
The line chart displays the monthly closing prices of Bacil Pharma with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Bacil Pharma shares in 2025, see the table below.
Bacil Pharma Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 50.02 (+23.56%) | Price Action: 11 Nov 2024 High |
| 2025 Target 2 | 49.02 (+21.09%) | Price Action: 12 Nov 2024 High |
| 2025 Target 1 | 47.9 (+18.32%) | Price Action: 07 Feb 2025 High |
| Current Price | 40.48 | Bacil Pharma's share price as of 28 Feb 2025 |
| Stop Loss 1 | 37.23 (-8.02%) | Price Action: 18 Oct 2024 High |
| Stop Loss 2 | 36.5 (-9.84%) | Price Action: 17 Oct 2024 High |
| Stop Loss 3 | 35.79 (-11.59%) | Price Action: 16 Oct 2024 High |
Short-Term Technical Outlook
Current Technical Position: Bacil Pharma is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹43.34 serves as the nearest technical reference point.
Historical Returns: 3-month: -10.31% | 6-month: +115.78% | 1-year: +297.12%
Bacil Pharma Share Price Target For 2026
The line chart displays the monthly closing prices of Bacil Pharma with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Bacil Pharma shares in 2026, see the table below.
Bacil Pharma Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 79.5 (+96.39%) | Price Action: Chart |
| 2026 Target 2 | 78.02 (+92.73%) | Fibonacci Extension Level 64.90% |
| 2026 Target 1 | 76.21 (+88.26%) | Fibonacci Extension Level 123.60% |
| Current Price | 40.48 | Bacil Pharma's share price as of 28 Feb 2025 |
| Stop Loss 1 | 31.81 (-21.42%) | Price Action: 08 Oct 2024 High |
| Stop Loss 2 | 31.19 (-22.95%) | Price Action: 07 Oct 2024 High |
| Stop Loss 3 | 30.58 (-24.46%) | Price Action: 04 Oct 2024 High |
Long-Term Technical Outlook
52-Week Range Analysis: Bacil Pharma is currently trading at 57.8% of its 52-week range (₹10.2 - ₹62.56).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +297.12% | 3-year: +357.36% | 5-year: +2,144.57%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Bacil Pharma Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹40.48 | ||
| 2025 | ₹81.04 | +100.19% | ₹82.26 |
| 2026 | ₹113.14 | +39.61% | ₹114.84 |
| 2027 | ₹173.49 | +53.34% | ₹176.09 |
| 2028 | ₹245.61 | +41.57% | ₹249.29 |
| 2029 | ₹353.73 | +44.02% | ₹359.04 |
| 2030 | ₹483.90 | +36.79% | ₹491.16 |
| 2031 | ₹666.02 | +37.63% | ₹676.01 |
| 2032 | ₹868.18 | +30.35% | ₹881.20 |
| 2033 | ₹1,151.23 | +32.6% | ₹1,168.50 |
| 2034 | ₹1,588.88 | +38.01% | ₹1,612.71 |
| 2035 | ₹2,043.89 | +28.63% | ₹2,074.55 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Bacil Pharma Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 27.73 Crore | Market valuation of Bacil Pharma's shares. |
| Net Income (TTM) | -5.9 Lakh | Net Profit or Loss after all the expenses over the past twelve months. |
Is Bacil Pharma A Good Buy For Long Term?
Bacil Pharma, a small-cap stock with a market capitalization of ₹27.73 crore, shows extraordinary growth: 580.87% YTD, 820.33% over three years, and a staggering 1788.69% over five years. While these returns are impressive, such dramatic growth often indicates high risk. For long-term investors, this level of volatility is a significant concern. Therefore, Bacil Pharma is not a good buy for long-term investment given its inherent risk despite past performance. Consider diversification and thorough due diligence before any investment.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
